Versatility on demand - The case for semi-solid micro-extrusion in pharmaceutics.
3D-printing
Additive manufacturing
Critical quality attributes
Drug delivery systems
Personalized therapy
Process analytical technology (PAT)
Process and formulation requirements
Process models
Semi-solid micro-extrusion
Journal
Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
30
11
2020
revised:
21
01
2021
accepted:
18
02
2021
pubmed:
12
3
2021
medline:
18
11
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
Since additive manufacturing of pharmaceuticals has been introduced as viable method to produce individualized drug delivery systems with complex geometries and release profiles, semi-solid micro-extrusion has shown to be uniquely beneficial. Easy incorporation of actives, room-temperature processability and avoidance of cross-contamination by using disposables are some of the advantages that led many researchers to focus their work on this technology in the last few years. First acceptability and in-vivo studies have brought it closer towards implementation in decentralized settings. This review covers recently established process models in light of viscosity and printability discussions to help develop high quality printed medicines. Quality defining formulation and process parameters to characterize the various developed dosage forms are presented before critically discussing the role of semi-solid micro-extrusion in the future of personalized drug delivery systems. Remaining challenges regarding regulatory guidance and quality assurance that pose the last hurdle for large scale and commercial manufacturing are addressed.
Identifiants
pubmed: 33705878
pii: S0169-409X(21)00059-4
doi: 10.1016/j.addr.2021.02.013
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104-126Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.